Agilent Technologies, Inc. (0HAV.L)
USD 102.88
(0.03%)
USD 102.88
(0.03%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 3.46 Billion USD | -6.9% |
| 2022 | 3.72 Billion USD | 9.25% |
| 2021 | 3.4 Billion USD | 20.09% |
| 2020 | 2.83 Billion USD | 1.14% |
| 2019 | 2.8 Billion USD | 4.39% |
| 2018 | 2.68 Billion USD | 11.54% |
| 2017 | 2.4 Billion USD | 9.65% |
| 2016 | 2.19 Billion USD | 7.64% |
| 2015 | 2.04 Billion USD | -43.2% |
| 2014 | 3.59 Billion USD | 1.64% |
| 2013 | 3.53 Billion USD | -1.91% |
| 2012 | 3.6 Billion USD | 2.13% |
| 2011 | 3.52 Billion USD | 20.44% |
| 2010 | 2.93 Billion USD | 27.84% |
| 2009 | 2.29 Billion USD | -28.29% |
| 2008 | 3.19 Billion USD | 7.65% |
| 2007 | 2.96 Billion USD | 11.7% |
| 2006 | 2.65 Billion USD | 5.39% |
| 2005 | 2.52 Billion USD | -19.24% |
| 2004 | 3.12 Billion USD | 36.14% |
| 2003 | 2.29 Billion USD | -0.95% |
| 2002 | 2.31 Billion USD | -28.3% |
| 2001 | 3.23 Billion USD | -38.49% |
| 2000 | 5.25 Billion USD | 33.17% |
| 1999 | 3.94 Billion USD | 0.66% |
| 1998 | 3.91 Billion USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 856 Million USD | -6.24% |
| 2024 Q3 | 855 Million USD | -0.12% |
| 2024 Q1 | 913 Million USD | -0.22% |
| 2023 FY | 3.46 Billion USD | -6.9% |
| 2023 Q3 | 658 Million USD | -28.79% |
| 2023 Q1 | 968 Million USD | -4.35% |
| 2023 Q2 | 924 Million USD | -4.55% |
| 2023 Q4 | 915 Million USD | 39.06% |
| 2022 Q1 | 910 Million USD | 1.11% |
| 2022 Q3 | 939 Million USD | 9.06% |
| 2022 FY | 3.72 Billion USD | 9.25% |
| 2022 Q4 | 1.01 Billion USD | 7.77% |
| 2022 Q2 | 861 Million USD | -5.38% |
| 2021 Q4 | 900 Million USD | 5.63% |
| 2021 Q1 | 838 Million USD | 6.35% |
| 2021 Q2 | 817 Million USD | -2.51% |
| 2021 Q3 | 852 Million USD | 4.28% |
| 2021 FY | 3.4 Billion USD | 20.09% |
| 2020 Q2 | 657 Million USD | -9.13% |
| 2020 Q4 | 788 Million USD | 17.79% |
| 2020 FY | 2.83 Billion USD | 1.14% |
| 2020 Q3 | 669 Million USD | 1.83% |
| 2020 Q1 | 723 Million USD | -1.9% |
| 2019 FY | 2.8 Billion USD | 4.39% |
| 2019 Q4 | 737 Million USD | 6.5% |
| 2019 Q3 | 692 Million USD | 3.44% |
| 2019 Q2 | 669 Million USD | -5.37% |
| 2019 Q1 | 707 Million USD | -0.28% |
| 2018 Q4 | 709 Million USD | 7.26% |
| 2018 Q1 | 673 Million USD | 4.02% |
| 2018 Q3 | 661 Million USD | 2.64% |
| 2018 Q2 | 644 Million USD | -4.31% |
| 2018 FY | 2.68 Billion USD | 11.54% |
| 2017 Q1 | 574 Million USD | -2.38% |
| 2017 Q4 | 647 Million USD | 8.56% |
| 2017 Q3 | 596 Million USD | 0.68% |
| 2017 FY | 2.4 Billion USD | 9.65% |
| 2017 Q2 | 592 Million USD | 3.14% |
| 2016 FY | 2.19 Billion USD | 7.64% |
| 2016 Q4 | 588 Million USD | 8.49% |
| 2016 Q2 | 530 Million USD | -1.3% |
| 2016 Q1 | 537 Million USD | 0.37% |
| 2016 Q3 | 542 Million USD | 2.26% |
| 2015 Q4 | 535 Million USD | 4.29% |
| 2015 Q2 | 480 Million USD | -6.43% |
| 2015 Q1 | 513 Million USD | -42.81% |
| 2015 FY | 2.04 Billion USD | -43.2% |
| 2015 Q3 | 513 Million USD | 6.88% |
| 2014 FY | 3.59 Billion USD | 1.64% |
| 2014 Q3 | 914 Million USD | 1.67% |
| 2014 Q4 | 897 Million USD | -1.86% |
| 2014 Q1 | 883 Million USD | -2.75% |
| 2014 Q2 | 899 Million USD | 1.81% |
| 2013 FY | 3.53 Billion USD | -1.91% |
| 2013 Q2 | 891 Million USD | 1.25% |
| 2013 Q3 | 856 Million USD | -3.93% |
| 2013 Q4 | 908 Million USD | 6.07% |
| 2013 Q1 | 880 Million USD | -4.56% |
| 2012 FY | 3.6 Billion USD | 2.13% |
| 2012 Q4 | 922 Million USD | 3.6% |
| 2012 Q3 | 890 Million USD | -3.05% |
| 2012 Q2 | 918 Million USD | 5.03% |
| 2012 Q1 | 874 Million USD | -5.1% |
| 2011 FY | 3.52 Billion USD | 20.44% |
| 2011 Q3 | 892 Million USD | -0.89% |
| 2011 Q1 | 816 Million USD | -2.16% |
| 2011 Q2 | 900 Million USD | 10.29% |
| 2011 Q4 | 921 Million USD | 3.25% |
| 2010 Q4 | 834 Million USD | 15.03% |
| 2010 Q3 | 725 Million USD | 1.97% |
| 2010 Q2 | 711 Million USD | 7.73% |
| 2010 FY | 2.93 Billion USD | 27.84% |
| 2010 Q1 | 660 Million USD | 4.1% |
| 2009 Q4 | 634 Million USD | 17.63% |
| 2009 FY | 2.29 Billion USD | -28.29% |
| 2009 Q1 | 589 Million USD | -29.04% |
| 2009 Q2 | 530 Million USD | -10.02% |
| 2009 Q3 | 539 Million USD | 1.7% |
| 2008 FY | 3.19 Billion USD | 7.65% |
| 2008 Q1 | 756 Million USD | -4.3% |
| 2008 Q3 | 803 Million USD | -0.5% |
| 2008 Q2 | 807 Million USD | 6.75% |
| 2008 Q4 | 830 Million USD | 3.36% |
| 2007 Q2 | 730 Million USD | 5.64% |
| 2007 Q4 | 790 Million USD | 4.22% |
| 2007 Q3 | 758 Million USD | 3.84% |
| 2007 Q1 | 691 Million USD | 51.54% |
| 2007 FY | 2.96 Billion USD | 11.7% |
| 2006 Q2 | 732 Million USD | 7.81% |
| 2006 Q3 | 791 Million USD | 8.06% |
| 2006 Q4 | 456 Million USD | -42.35% |
| 2006 FY | 2.65 Billion USD | 5.39% |
| 2006 Q1 | 679 Million USD | 214.35% |
| 2005 Q3 | 765 Million USD | -3.16% |
| 2005 Q4 | 216 Million USD | -71.76% |
| 2005 FY | 2.52 Billion USD | -19.24% |
| 2005 Q1 | 751 Million USD | -3.72% |
| 2005 Q2 | 790 Million USD | 5.19% |
| 2004 Q4 | 780 Million USD | -2.01% |
| 2004 Q3 | 796 Million USD | -1.49% |
| 2004 Q1 | 739 Million USD | 3.94% |
| 2004 FY | 3.12 Billion USD | 36.14% |
| 2004 Q2 | 808 Million USD | 9.34% |
| 2003 Q1 | 529 Million USD | -14.68% |
| 2003 FY | 2.29 Billion USD | -0.95% |
| 2003 Q4 | 711 Million USD | 29.74% |
| 2003 Q3 | 548 Million USD | 8.3% |
| 2003 Q2 | 506 Million USD | -4.35% |
| 2002 FY | 2.31 Billion USD | -28.3% |
| 2002 Q4 | 620 Million USD | 13.76% |
| 2002 Q3 | 545 Million USD | -9.62% |
| 2002 Q2 | 603 Million USD | 10.04% |
| 2002 Q1 | 548 Million USD | 69.66% |
| 2001 Q1 | 1.39 Billion USD | -15.12% |
| 2001 Q4 | 323 Million USD | -51.06% |
| 2001 Q3 | 660 Million USD | -32.38% |
| 2001 Q2 | 976 Million USD | -29.89% |
| 2001 FY | 3.23 Billion USD | -38.49% |
| 2000 Q3 | 1.3 Billion USD | 6.29% |
| 2000 Q1 | 1.08 Billion USD | -55.64% |
| 2000 FY | 5.25 Billion USD | 33.17% |
| 2000 Q2 | 1.22 Billion USD | 12.71% |
| 2000 Q4 | 1.64 Billion USD | 26.06% |
| 1999 Q4 | 2.44 Billion USD | 17.3% |
| 1999 Q3 | 2.08 Billion USD | 3.83% |
| 1999 FY | 3.94 Billion USD | 0.66% |
| 1999 Q2 | 2.01 Billion USD | 12.54% |
| 1999 Q1 | 1.78 Billion USD | 0.0% |
| 1998 FY | 3.91 Billion USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | -156333.409% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -1147250.993% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 4166.138% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -19906.929% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -128.278% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -857.103% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 1107128.754% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -1316.975% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | -81.95% |
| bluebird bio, Inc. | -4.03 Million USD | 86080.149% |
| Blueprint Medicines Corporation | 236.58 Million USD | -1364.596% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -23321.657% |
| Imunon, Inc. | -720 Thousand USD | 481346.658% |
| Adicet Bio, Inc. | -6.09 Million USD | 56921.909% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -628.103% |
| Dynavax Technologies Corporation | 182.11 Million USD | -1802.623% |
| Editas Medicine, Inc. | -99.52 Million USD | 3581.432% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -907.56% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -4642.223% |
| Exelixis, Inc. | 1.75 Billion USD | -97.137% |
| FibroGen, Inc. | 128.9 Million USD | -2588.047% |
| Geron Corporation | -123.5 Million USD | 2905.6% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -444.048% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -34405.079% |
| Illumina, Inc. | 2.74 Billion USD | -26.276% |
| Incyte Corporation | 3.44 Billion USD | -0.708% |
| Insmed Incorporated | 239.63 Million USD | -1345.949% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 968.87% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -345.079% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 36322.036% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 33.861% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 1143664.356% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | -59.746% |
| Evolus, Inc. | 140.52 Million USD | -2365.736% |
| Myriad Genetics, Inc. | 476.4 Million USD | -627.33% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | -87.561% |
| OPKO Health, Inc. | 318.12 Million USD | -989.188% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -217.019% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -561.585% |
| Verastem, Inc. | -62 Thousand USD | 5588809.677% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 86.936% |
| Waters Corporation | 1.76 Billion USD | -96.742% |
| Zoetis Inc. | 5.83 Billion USD | 40.607% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 59.742% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 77.24% |
| Biogen Inc. | 7.3 Billion USD | 52.549% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 7744.788% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 69.34% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 11217.293% |
| Homology Medicines, Inc. | -7.22 Million USD | 48031.941% |
| Nektar Therapeutics | 53.47 Million USD | -6379.3% |
| TG Therapeutics, Inc. | 219.1 Million USD | -1481.412% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 1186743.836% |
| Perrigo Company plc | 1.68 Billion USD | -106.201% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 17689.725% |